Approach to cardiovascular disease prevention in patients with chronic kidney disease

Current Treatment Options in Cardiovascular Medicine

Volumn 14, Issue 4, 2012, Pages 391-413

  Karohl, Cristina ^a,b   Raggi, Paolo ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Cardiovascular disease; Chronic kidney disease; Prevention; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITRIOL; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; COLECALCIFEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ERGOCALCIFEROL; EZETIMIBE; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LISINOPRIL; LOSARTAN; METFORMIN; ORAL ANTIDIABETIC AGENT; PARICALCITOL; PHOSPHATE BINDING AGENT; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; TRANDOLAPRIL; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACIDEMIA; ACUTE KIDNEY FAILURE; AIRWAY RESISTANCE; ALBUMINURIA; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ASTHMA; ATRIOVENTRICULAR BLOCK; BLEEDING; BLOOD PRESSURE REGULATION; BLOOD VESSEL CALCIFICATION; BODY MASS; BRADYCARDIA; BRONCHOSPASM; CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUGHING; CREATINE KINASE BLOOD LEVEL; DEHYDRATION; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; DYSPEPSIA; EARLY INTERVENTION; ENZYME INHIBITION; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GOUT; HEALTH CARE PLANNING; HEALTH PROGRAM; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEARTBURN; HEMATURIA; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; IMPOTENCE; INTESTINE ABSORPTION; INTESTINE ULCER; IRON THERAPY; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LIVER DYSFUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; MINERAL DEFICIENCY; MINERAL METABOLISM; MONOTHERAPY; MYALGIA; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEPHROSCLEROSIS; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; OTOTOXICITY; PATIENT IDENTIFICATION; PHOTOSENSITIVITY DISORDER; PHYSICAL ACTIVITY; POLYURIA; POPULATION RESEARCH; PROTEIN SECRETION; PROTEINURIA; RECOMMENDED DRUG DOSE; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SIDE EFFECT; SMOKING CESSATION; SODIUM RESTRICTION; SOLITARY KIDNEY; STOMACH PAIN; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VALVULAR HEART DISEASE; VITAMIN SUPPLEMENTATION; VOMITING; WEAKNESS; WEIGHT REDUCTION;

EID: 84865698822     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-012-0189-2     Document Type: Review

References (108)

1. Couser WG, Riella MC. World Kidney Day 2011: Protect your kidneys, save your heart. Clin J Am Soc Nephrol. 2011;6(2):235-8. This is an editorial regarding the 2011 World Kidney Day ("Protect your Kidneys, Save your Heart") that focuses on early detection and prevention of kidney disease with the purpose to prevent cardiovascular disease.
2. K/DOQI clinical practice guidelines for chronic kidney disease. evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.
3. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: Systematic review. BMC Publ Health. 2008;8:117.
4. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298 (17):2038-47. (Pubitemid 350074801)
5. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489-95. (Pubitemid 41725146)
6. U S Renal Data System, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2011.
7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305.
8. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet. 2010;375(9731):2073-81. This meta-analysis concluded that a glomerular filtration rate below 60 mL/min/1.73 m2 and albumin-creatinine ratio of10 mg/g or above are independent predictors of mortality in the general population.
9. McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, et al. Independent components of chronic kidney disease as a cardiovascular risk state: Results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007;167 (11):1122-9. (Pubitemid 46919814)
10. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341-52.
11. Astor BC, Hallan SI, Miller 3rd ER, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008;167(10):1226-34. (Pubitemid 351670638)
12. Muntner P, Bowling CB, Gao L, Rizk D, Judd S, Tanner RM, et al. Age-specific association of reduced estimated glomerular filtration rate and albuminuria with all-cause mortality. Clin J Am Soc Nephrol. 2011;6(9):2200-7.
13. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303(5):423-9.
14. Bello AK, Hemmelgarn B, Lloyd A, James MT, Manns BJ, Klarenbach S, et al. Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes. Clin J Am Soc Nephrol. 2011;6(6):1418-26. In this population-based longitudinal study, proteinuria showed incremental prognostic value at every level of glomerular filtration rate as a predictor of cardiovascular events; the authors suggested that proteinuria should be measured along with glomerular filtration rate for better risk stratification in chronic kidney disease.
15. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005;16:529-38. (Pubitemid 41725151)
16. Ritz E, Wanner C. The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol. 2008;3:920-9.
17. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol. 2009;4:S79-91.
18. Plantinga LC, Miller 3rd ER, Stevens LA, Saran R, Messer K, Flowers N, et al. Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006. Hypertension. 2009;54(1):47-56.
19. Hackam DG, Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NR, et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 -therapy. Can J Cardiol. 2010;26(5):249-58.
20. Holt S, Goldsmith D. Renal Association Clinical Practice Guideline on cardiovascular disease in CKD. Nephron Clin Pract. 2011;118 Suppl 1:c125-44. This recent clinical practice guideline provides recommendations on the prevention and management of cardiovascular disease in patients with chronic kidney disease.
21. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev. 2009;3.
22. Wright JTJ, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA. 2002;288(19):2421-31. (Pubitemid 35340538)
23. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27(7):1360-9.
24. Cushman WC, Evans GW, Byington RP, Goff DCJ, Grimm RHJ, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-85.
25. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria.AmJ Kidney Dis. 2007;49(1):12-26. (Pubitemid 44918179)
26. Appel LJ, Wright JTJ, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363(10):918-29. This clinical study among 1094 hypertensive black patients with chronic kidney disease suggests that the presence of proteinuria should be used as a guide to determine the blood pressure goal in chronic kidney disease patients.
27. Lewis JB. Blood pressure control in chronic kidney disease: Is less really more? J Am Soc Nephrol. 2010;21(7):1086-92.
28. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12-S154.
29. Wühl E, Schaefer F. Medscape. Managing kidney disease with blood-pressure control. Nat Rev Nephrol. 2011;7(8):434-44.
30. Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2011.
31. Maione A, Navaneethan SD, Graziano G, Mitchell R, Johnson D, Mann JF, et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro-and macroalbuminuria and other cardiovascular risk factors: A systematic review of randomized controlled trials. Nephrol Dial Transplant. 2011;26(9):2827-47. This systematic review discusses the benefits of ACE inhibitors and ARBs on renal and cardiovascular outcomes.
32. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358 (15):1547-59. (Pubitemid 351522739)
33. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2641-50.
34. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2009;3.
35. Lizakowski S, Tylicki L, Renke M, Rutkowski P,Heleniak Z, Slawinska-Morawska M, et al. Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: A double-blind, crossover, randomised, controlled trial. Int Urol Nephrol. 2012.
36. Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care. 2009;32(10):1873-9.
37. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH, et al. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care. 2010;33(11):2304-9.
38. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med. 2000;160 (5):685-93. (Pubitemid 30140419)
39. McKenzie DB, Cowley AJ. Drug therapy in chronic heart failure. Postgrad Med J. 2003;79(937):634-42. (Pubitemid 38019213)
40. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004;109(8):1004-9. (Pubitemid 38282853)
41. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438-44. (Pubitemid 36543357)
42. Sica DA. Diuretic use in renal disease. Nat Rev Nephrol. 2011;8(2):100-9.
43. Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation. 2001;103(14):1869-74. (Pubitemid 32328400)
44. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol. 2010;6(6):319-30.
45. Kunz R, Friedrich C, Wolbers M, Mann JF. Metaanalysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30-48. (Pubitemid 351688350)
46. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110(18):2809-16. (Pubitemid 39473602)
47. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens. 2004;22(9):1805-11. (Pubitemid 39141974)
48. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review. BMJ. 2004;329(7470):828.
49. Ruggenenti P, Fassi A, Ilieva AP, Iliev IP, Chiurchiu C, Rubis N, et al. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: The BENEDICT-B randomized trial. J Hypertens. 2011;29 (2):207-16.
50. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003;41(4 Suppl 3):S1-91.
51. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-48. (Pubitemid 41058323)
52. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-407.
53. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease:meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336(7645):645-51. (Pubitemid 351481234)
54. Kendrick J, Shlipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: A post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis. 2010;55(1):42-9.
55. Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated highsensitivity C-reactive protein: A secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010;55(12):1266-73.
56. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-92. This randomized placebo-controlled trial evaluated the efficacy and safety of the combination of simvastatin plus ezetimibe in patients with moderate-to-severe chronic kidney disease. Events were significantly reduced in all pre-dialysis patients but not for those undergoing dialysis.
57. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3-46.
58. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterollowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.
59. Tonelli M, Moyé L, Sacks FM, Kiberd B, Curhan G, Investigators. CaRECT. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138(2):98-104. (Pubitemid 36222496)
60. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-91. (Pubitemid 351214285)
61. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-53. (Pubitemid 41817713)
62. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72. (Pubitemid 351831357)
63. Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, et al. Effect of aspirin on vascular and nonvascular outcomes: Meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(3):209-16.
64. Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: A post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56(12):956-65.
65. Halimi JM, Giraudeau B, Vol S, Cacès E, Nivet H, Lebranchu Y, et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int. 2000;58(3):1285-92.
66. Critchley JA, Capewell S. WITHDRAWN: Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2012;2.
67. Schiffl H, Lang SM, Fischer R. Stopping smoking slows accelerated progression of renal failure in primary renal disease. J Nephrol. 2002;15(3):270-4. (Pubitemid 34830534)
68. Thijssen DH, Maiorana AJ, O'Driscoll G, Cable NT, Hopman MT, Green DJ. Impact of inactivity and exercise on the vasculature in humans. Eur J Appl Physiol. 2010;108(5):845-75.
69. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: A statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 2003;107(24):3109-16.
70. Guh DP, Zhang W, Bansback N,Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: A systematic review and metaanalysis. BMC Publ Health. 2009;9:88.
71. Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4 (10):1565-74.
72. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2010. 7th Edition, Washington, DC: U.S. Government Printing Office, December 2010.
73. KDIGO. Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease -Mineral and bone disorder (CKD-MBD). Kidney Int. 2009;113:S1-S130.
74. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-18. (Pubitemid 39031360)
75. Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant. 2009;24(5):1506-23.
76. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int. 2009;75:890-7.
77. Blair D, Byham-Gray L, Lewis E, McCaffrey S. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr. 2009;18(4):375-82. (Pubitemid 351818240)
78. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72(8):1004-13. (Pubitemid 47530570)
79. Pilz S, Tomaschitz A, Friedl C, Amrein K, Drechsler C, Ritz E, et al. Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant. 2011;26(11):3603-9.
80. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305 (23):2432-9.
81. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6(4):913-21. This review summarizes the current understanding of secondary hyperparathyroidism and strategies for SHPT treatment in chronic kidney disease patients.
82. Rostand SG, Drüeke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int. 1999;56(2):383-92. (Pubitemid 29353135)
83. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2009;20(2):381-7.
84. Martin KJ, González EA. Prevention and control of phosphate retention/hyperphosphatemia in CKDMBD: What is normal, when to start, and how to treat? Clin J Am Soc Nephrol. 2011;6(2):440-6. The authors review management of phosphate retention and hyperphosphatemia in chronic kidney disease and discuss when and how to optimize phosphate control to improve clinical outcomes.
85. Langman CB, Cannata-Andía JB. Calcium in chronic kidney disease: Myths and realities. Introduction. Clin J Am Soc Nephrol. 2010;5 Suppl 1:S1-2.
86. Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008;3 (4):1125-30.
87. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: A randomized trial. Clin J Am Soc Nephrol. 2009;4 (1):178-85.
88. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: A randomized clinical trial. Am J Kidney Dis. 2012;59(2):177-85.
89. Russo D,Miranda I, RuoccoC, Battaglia Y, Buonanno E, Manzi S, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72:1255-61. (Pubitemid 350059663)
90. Di Iorio B, Bellasi A, Russo D, Investigators. obotIS. Mortality in kidney disease patients treated with phosphate binders: A Randomized Study. Clin JAmSoc Nephrol. 2012. This study is the first to evaluate the effect of two phosphate binders, sevelamer and calcium carbonate, on mortality in chronic kidney disease stage 3 and 4 patients.
91. Chue CD, Townend JN, Steeds RP, Ferro CJ. Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: The CRIB-PHOS randomised controlled trial. Trials. 2011;12(1):30.
92. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-8. (Pubitemid 44967731)
93. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitaminDstatus and determinants of hypovitaminosis D. Osteoporos Int. 2009;20(11):1807-20.
94. Judd SE, Tangpricha V. Vitamin D deficiency and risk for cardiovascular disease. Am J Med Sci. 2009;338 (1):40-4.
95. Drechsler C, Pilz S, Obermayer-Pietsch B, Verduijn M, Tomaschitz A, Krane V, et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J. 2010;31 (18):2253-61.
96. Drechsler C, Verduijn M, Pilz S, Dekker FW, Krediet RT, Ritz E, et al. Vitamin D status and clinical outcomes in incident dialysis patients: Results from the NECOSAD study. Nephrol Dial Transplant. 2011;26 (3):1024-32.
97. Cheng J, Zhang W, Zhang X, Li X, Chen J. Efficacy and safety of paricalcitol therapy for chronic kidney disease: A meta-analysis. Clin J Am Soc Nephrol. 2012.
98. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol. 2008;19(8):1613-9.
99. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med. 2008;168(4):397-403. (Pubitemid 351350586)
100. Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A. Treatment of 25-OH Vitamin D Deficiency in Older Men With Chronic Kidney Disease Stages 3 and 4 Is Associated With Reduction in Cardiovascular Events. Am J Ther. 2011.
101. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA. 2012;307(7):674-84. This placebo-controlled trial in patients with chronic kidney disease stage 3 and 4 evaluated the effects of an active vitamin D analogue, paricalcitol, on left ventricular mass.
102. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003;42(Suppl 3):S1-S202.
103. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, et al. Achieving NKF-K/ DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67 (2):760-71. (Pubitemid 40139871)
104. Smajilovic S, Tfelt-Hansen J. Calcium acts as a first messenger through the calcium-sensing receptor in the cardiovascular system. Cardiovasc Res. 2007;75 (3):457-67. (Pubitemid 47080961)
105. Block GA, Zaun D, Smits G, Persky M, Brillhart S, Nieman K, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int. 2010;78(6):578-89.
106. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, et al. The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26(4):1327-39.
107. Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009;53(2):197-207.
108. Finch JL, Tokumoto M, Nakamura H, Yao W, Shahnazari M, Lane N, et al. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol. 2010;298(6):F1315-F22.